ADMA
Income statement / Annual
Last year (2024), ADMA Biologics, Inc.'s total revenue was $426.45 M,
an increase of 65.15% from the previous year.
In 2024, ADMA Biologics, Inc.'s net income was $197.67 M.
See ADMA Biologics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$426.45 M |
$258.21 M |
$154.08 M |
$80.94 M |
$42.22 M |
$29.35 M |
$16.99 M |
$22.76 M |
$10.66 M |
$7.18 M |
| Cost of Revenue |
$206.90 M
|
$169.27 M
|
$118.81 M
|
$79.77 M
|
$61.29 M
|
$39.50 M
|
$42.19 M
|
$29.16 M
|
$6.36 M
|
$4.31 M
|
| Gross Profit |
$219.55 M
|
$88.94 M
|
$35.27 M
|
$1.17 M
|
-$19.07 M
|
-$10.16 M
|
-$25.21 M
|
-$6.40 M
|
$4.30 M
|
$2.87 M
|
| Gross Profit Ratio |
0.51
|
0.34
|
0.23
|
0.01
|
-0.45
|
-0.35
|
-1.48
|
-0.28
|
0.4
|
0.4
|
| Research and Development Expenses |
$1.81 M
|
$3.30 M
|
$3.61 M
|
$3.65 M
|
$5.91 M
|
$2.34 M
|
$3.93 M
|
$6.23 M
|
$7.69 M
|
$7.02 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$22.50 M
|
$18.09 M
|
$8.49 M
|
$6.75 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$74.12 M
|
$59.02 M
|
$52.46 M
|
$42.90 M
|
$35.05 M
|
$25.91 M
|
$22.50 M
|
$18.09 M
|
$8.49 M
|
$6.75 M
|
| Other Expenses |
$0.00
|
$4.99 M
|
$18.56 M
|
$13.00 M
|
$4.89 M
|
$3.01 M
|
-$127,121.00
|
-$10,144.00
|
$4,496.00
|
$4.62 M
|
| Operating Expenses |
$75.94 M
|
$67.31 M
|
$74.63 M
|
$59.55 M
|
$45.84 M
|
$31.27 M
|
$35.08 M
|
$32.06 M
|
$21.63 M
|
$18.38 M
|
| Cost And Expenses |
$282.84 M
|
$236.58 M
|
$193.44 M
|
$139.32 M
|
$107.13 M
|
$70.77 M
|
$77.27 M
|
$61.23 M
|
$27.99 M
|
$22.69 M
|
| Interest Income |
$2.10 M
|
$1.62 M
|
$44,833.00
|
$34,532.00
|
$288,126.00
|
$800,785.00
|
$195,403.00
|
$57,228.00
|
$50,317.00
|
$37,830.00
|
| Interest Expense |
-$13.93 M
|
$25.03 M
|
$19.28 M
|
$13.06 M
|
$11.99 M
|
$8.99 M
|
$5.52 M
|
$3.29 M
|
$2.24 M
|
$1.84 M
|
| Depreciation & Amortization |
$0.00
|
$8.33 M
|
$7.11 M
|
$5.50 M
|
$3.94 M
|
$3.26 M
|
$3.45 M
|
$1.23 M
|
$469,576.00
|
$469,821.00
|
| EBITDA |
$138.98 M |
$5.12 M |
-$39.72 M |
-$53.33 M |
-$59.82 M |
-$36.03 M |
-$56.77 M |
-$39.31 M |
-$16.81 M |
-$15.66 M |
| EBITDA Ratio |
0.33
|
0.02
|
-0.25
|
-0.72
|
-1.52
|
-1.36
|
-3.34
|
-1.63
|
-1.58
|
-2.09
|
| Operating Income Ratio |
0.33
|
0.08
|
-0.26
|
-0.72
|
-1.54
|
-1.41
|
-3.55
|
-1.73
|
-1.63
|
-2.16
|
| Total Other Income/Expenses Net |
-$13.27 M
|
-$49.87 M
|
-$26.75 M
|
-$13.51 M
|
-$10.83 M
|
-$6.85 M
|
-$5.45 M
|
-$4.45 M
|
-$2.18 M
|
-$2.46 M
|
| Income Before Tax |
$125.71 M
|
-$28.24 M
|
-$65.90 M
|
-$71.65 M
|
-$75.75 M
|
-$48.28 M
|
-$65.74 M
|
-$43.76 M
|
-$19.52 M
|
-$17.97 M
|
| Income Before Tax Ratio |
0.29
|
-0.11
|
-0.43
|
-0.89
|
-1.79
|
-1.65
|
-3.87
|
-1.92
|
-1.83
|
-2.5
|
| Income Tax Expense |
-$71.96 M
|
$0.00
|
$19.28 M
|
$12.81 M
|
$11.86 M
|
$8.77 M
|
$5.45 M
|
$4.45 M
|
$2.18 M
|
$2.46 M
|
| Net Income |
$197.67 M
|
-$28.24 M
|
-$85.18 M
|
-$84.45 M
|
-$87.61 M
|
-$57.05 M
|
-$65.74 M
|
-$43.76 M
|
-$19.52 M
|
-$17.97 M
|
| Net Income Ratio |
0.46
|
-0.11
|
-0.55
|
-1.04
|
-2.07
|
-1.94
|
-3.87
|
-1.92
|
-1.83
|
-2.5
|
| EPS |
0.85 |
-0.13 |
-0.43 |
-0.61 |
-1.02 |
-1.05 |
-1.45 |
-1.91 |
-1.61 |
-1.73 |
| EPS Diluted |
0.81 |
-0.13 |
-0.43 |
-0.61 |
-1.02 |
-1.05 |
-1.45 |
-1.91 |
-1.61 |
-1.73 |
| Weighted Average Shares Out |
$233.08 M
|
$223.98 M
|
$197.87 M
|
$139.58 M
|
$86.15 M
|
$54.35 M
|
$45.19 M
|
$22.90 M
|
$12.15 M
|
$10.41 M
|
| Weighted Average Shares Out Diluted |
$243.34 M
|
$223.98 M
|
$197.87 M
|
$139.58 M
|
$86.15 M
|
$54.35 M
|
$45.19 M
|
$22.90 M
|
$12.15 M
|
$10.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
